Back to today’s briefing

Story perspectives

Obesity Drug Switch: Americans Face Tough Choices Amid Insurance Denials

5/12/2025

50 10

Summary

Story summary

Tens of thousands of Americans face a daunting switch from the more effective obesity drug Zepbound to Wegovy, thanks to pharmacy benefit managers like CVS Health’s Caremark. This controversial decision underscores the troubling reality of insurance denials and hidden agreements in drug pricing, leaving many to grapple with the consequences of corporate choices over their health.

1 of 1

Story summary

Tens of thousands of Americans face a daunting switch from the more effective obesity drug Zepbound to Wegovy, thanks to pharmacy benefit managers like CVS Health’s Caremark. This controversial decision underscores the troubling reality of insurance denials and hidden agreements in drug pricing, leaving many to grapple with the consequences of corporate choices over their health.